People differ from one another in millions of ways. For starters, there is eye color, hair color, body build, and tendencies toward certain diseases and conditions. We know that genes determine these differences. Now, we also are learning that genes affect how our bodies respond to disease. Through the study of genetic links between patients and chronic diseases, Geisinger Health System researchers are hoping to gain a better understanding of how to prevent, diagnose and treat these diseases.
A new program at Geisinger called MyCode is capitalizing on the health system’s unique ability to utilize its integrated infrastructure to link genomic information with one of the nation's most advanced electronic health record (EHR) systems and fastest growing biobanks. The result is a powerful tool that is the bridge to Geisinger's personalized medicine program – an initiative that promises to ultimately re-engineer the paradigm of healthcare from reactive to predictive and, with the help of researchers and physicians, engage patients in their personal health and wellness.
Geisinger patients learn about MyCode at Geisinger Medical Group sites and about 90 percent choose to participate. With written consent, participants agree to provide a deoxyribonucleic acid (DNA) sample – chemical material that is inherited and extracted from a blood sample - at their next scheduled blood draw. From there, the sample is linked with EHR information and routed to the system’s biobank for quick researcher access.
Since launching the MyCode pilot program two years ago, researchers have collected 20,000 DNA samples – proportionately more samples than from any other biobanking facility nationwide. Samples generally fall into two groups: those from patients seeking general health and wellness care from their family physicians and those from patients seeking specialty medical care, such as bariatric surgery.
These samples are helping Geisinger researchers gain critical insight into patients’ risk of chronic health conditions, such as abdominal aortic aneurysms (AAA), severe asthma, depression, obesity, familial ureterocoele, digoxin/phenytoin toxicity, overactive bladder syndrome and various pain conditions.
“This information will ultimately improve health by motivating people to make positive lifestyle changes, such as exercising, eating healthy, quitting smoking as well as decisions to seek further medical evaluation and preventive strategies,” said Geisinger Center for Health Research Director Walter “Buzz” Stewart, Ph.D., M.P.H.
A number of safeguards protect the privacy of participants’ genetic and EHR information. Confidentiality and subject anonymity are strictly maintained by de-identifying the samples. Samples are assigned specific identification numbers, encoded, encrypted and entered into a secure database. A governance board – with Geisinger and non-Geisinger representation - meets several times a year to audit the process.
“The goal of MyCode is to translate genetic data into specific knowledge about a disease that is clinically relevant and will enhance patient care,” said Glenn Gerhard, M.D., staff scientist and director of Geisinger’s Genomics Core. “Geisinger’s integrated healthcare delivery system, geography, as well as its electronic health record, biobank, lab, data, and basic science and population-based research programs, make this an outstanding environment for discovery."
“MyCode aims to discover genes that increase a person’s risk of chronic disease and help us understand why people respond differently to treatments,” explained Weis Center for Research Director David Carey, Ph.D. “The more we know about the causes of disease, the greater our ability to provide more effective treatment and, ultimately, prevent disease from occurring.”
According to Carey, by matching genes with a comprehensive profile of a specific chronic condition, researchers are able to study groups of patients with similar signs and symptoms and begin to predict and understand how they will respond to a specific treatment or medication.
“This project provides the opportunity to move genetics from the laboratory directly to patient care,” explained Stewart. “MyCode is driving research that promises to improve the health and healthcare of patients nationwide.”About Geisinger Health System
Patricia Urosevich | Newswise Science News
Further reports about: > DNA > Depression > MyCode Project > Personalized Medicine > abdominal aortic aneurysms > biobanking facility > body build > chronic disease > chronic diseases > deoxyribonucleic acid (DNA) sample > digoxin/phenytoin toxicity > eye color > genes > genomic information > hair color > overactive bladder syndrome
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy